| Original language | English |
|---|---|
| Article number | e005973 |
| Journal | Circulation: Cardiovascular Interventions |
| Volume | 10 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 1 Oct 2017 |
Funding
The Cardiovascular Center Aalst receives grant support from Abbott, Boston Scientific, Biotronik, and St Jude Medical and receives consulting fees on behalf of Dr De Bruyne from St. Jude Medical, Opsens, and Boston Scientific outside of the submitted work. Dr De Bruyne is a shareholder for Siemens, GE, Bayer, Philips, HeartFlow, Edwards Life Sciences, Sanofi, and Omega Pharma. The other authors report no conflicts.
Keywords
- Drug-Eluting Stents
- Fractional Flow Reserve, Myocardial
- Percutaneous Coronary Intervention
- Prognosis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver